StockData
aTYR PHARMA INC logo

aTYR PHARMA INC (ATYR) shareholders

ATYRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30
$4.99−0.25 (-4.77%)

Close on Nov 17, 2026Market cap $489.46MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
41.4%
41M of 98M shares
Institutional holders
90
16 new, 35 sold out
Net institutional buying
-15M
In Q2 2026
Insider trades, 12 months
1 buys · 3 sales
Net bought $43.71K

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Federated Hermes, Inc.
Joint filing with Voting Shares Irrevocable Trust (8.68%), Thomas R. Donahue (8.68%) and 2 more
8,509,6788.68%13G (passive) amendmentJun 30, 2026
FMR LLC
Joint filing with Abigail P. Johnson (6.10%)
5,935,9006.10%13G (passive) amendmentMay 29, 2026
Ann C. Donahue
Joint filing with Federated Hermes, Inc. (5.06%), Voting Shares Irrevocable Trust (5.06%) and 2 more
4,965,4145.06%13G (passive) amendmentSep 30, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of ATYRValueChange% of portfolio
Federated Hermes, Inc.8,509,6788.68%$5.08M−2,000,0000.01%
Vanguard Capital Management LLC3,808,0913.88%$2.27M−4,0410.00%
Kalehua Capital Management LLC3,576,3343.65%$2.13MNew0.68%
Gsa Capital Partners Llp3,454,8633.52%$2.06M+1,770,2770.13%
Aqr Capital Management LLC2,610,5482.66%$1.56M+2,114,5300.00%
FMR LLC2,471,4182.52%$1.47M−12,235,4250.00%
BlackRock, Inc.1,827,3321.86%$1.09M−4,616,5720.00%
Jane Street Group, LLC1,721,2971.75%$1.03M+1,672,7950.00%
UBS Group AG1,531,1511.56%$914.10K−2,336,0620.00%
Morgan Stanley1,343,6361.37%$801.88K+118,1690.00%
Two Sigma Investments, LP1,245,1471.27%$743.10K+100,5820.00%
Citadel Advisors LLC1,242,0671.27%$741.27K+1,194,6950.00%
Geode Capital Management, LLC1,177,0201.20%$702.73K−1,208,4650.00%
Susquehanna International Group, Llp747,0390.76%$445.83K−119,7050.00%
Millennium Management LLC656,0510.67%$391.53K−985,1950.00%
Goldman Sachs Group Inc641,2080.65%$382.67K+357,9720.00%
Vanguard Fiduciary Trust Co576,1250.59%$343.95K−75,7070.00%
State Street Corp494,9510.50%$295.39K−1,259,4480.00%
Marshall Wace, Llp368,1200.38%$220.87K+230,0020.00%
XTX Topco Ltd226,6780.23%$135.28K+115,2550.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 20269041M41.4%16 / 2930 / 3512M28M
Q1 202611156M57.1%36 / 2632 / 811M5M
Q4 20258455M55.9%16 / 2425 / 346M13M
Q3 202510362M63.3%34 / 3325 / 3915M20M
Q2 202511066M67.8%52 / 2524 / 2912M8M
Q1 20258762M63.0%26 / 3614 / 1613M6M
Q4 20247755M56.0%30 / 2412 / 813M5M
Q3 20245648M48.8%15 / 1512 / 54M6M
Q2 20244751M52.1%8 / 2211 / 1712M3M
Q1 20245642M42.7%15 / 2110 / 55M5M
Q4 20234641M42.1%9 / 1510 / 39M4M
Q3 20234037M37.4%7 / 618 / 83M2M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

101 funds held ATYR in Q1 2026, 25% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of ATYRValue% of fundAs of
Federated Hermes Kaufmann Fund4,367,2904.45%$2.12M0.04%Jul 31, 2026
Fidelity Growth Company Fund4,216,8324.30%$2.29M0.00%May 31, 2026
Federated Hermes Kaufmann Small Cap Fund4,061,2884.14%$1.97M0.07%Jul 31, 2026
Vanguard Total Stock Market Index Fund2,650,7882.70%$1.58M0.00%Jun 30, 2026
Select Biotechnology Portfolio1,754,5941.79%$951.87K0.02%May 31, 2026
Vanguard Extended Market Index Fund1,054,5561.08%$629.36K0.00%Jun 30, 2026
Fidelity Extended Market Index Fund550,0580.56%$298.41K0.00%May 31, 2026
Vanguard Russell 2000 Index Fund488,8230.50%$265.19K0.00%May 31, 2026
Fidelity Total Market Index Fund168,1170.17%$91.20K0.00%May 31, 2026
iShares Core S&P Total U.S. Stock Market ETF146,0270.15%$87.15K0.00%Jun 30, 2026
Fidelity Series Total Market Index Fund145,3590.15%$78.86K0.00%May 31, 2026
Vanguard Russell 2000 Growth Index Fund85,8810.09%$46.59K0.00%May 31, 2026
Federated Hermes Kaufmann Fund II81,1000.08%$48.40K0.04%Jun 30, 2026
Fidelity Nasdaq Composite Index Fund66,6690.07%$36.17K0.00%May 31, 2026
Goldman Sachs Absolute Return Tracker Fund66,0340.07%$39.41K0.00%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Sanjay ShuklaPresident and CEO, Director153,5530.16%Feb 4, 2026
Brandon YarasChief Financial Officer––Oct 1, 2026
Jill Marie BroadfootChief Financial Officer37,2960.04%Feb 4, 2026
Nancy DenyesGeneral Counsel33,1240.03%Feb 4, 2026
Paul SchimmelDirector2,201,0562.24%May 28, 2026
Jane A. GrossDirector9,7500.01%May 13, 2026
Sara ZaknoenDirector6,0000.01%May 13, 2026
Svetlana LucasDirector6,0000.01%May 13, 2026
Timothy CoughlinDirector56,0000.06%May 13, 2026
Eric BenevichDirector––May 13, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Paul Schimmel
Director
May 27, 2026Buy+100,000$0.50$50.00K779,143
Nancy Denyes
General Counsel
Feb 4, 2026Sale−1,118$0.98$1.10K33,124
Jill Marie Broadfoot
Chief Financial Officer
Feb 4, 2026Sale−1,558$0.98$1.53K37,296
Sanjay Shukla
President and CEO, Director
Feb 4, 2026Sale−3,745$0.98$3.67K153,553
Nancy Denyes
General Counsel
Feb 3, 2026Option exercise+2,687––34,242
Jill Marie Broadfoot
Chief Financial Officer
Feb 3, 2026Option exercise+3,750––38,854
Sanjay Shukla
President and CEO, Director
Feb 3, 2026Option exercise+10,375––157,298
Paul Schimmel
Director
Oct 9, 2025Buy+317,999$0.94$298.92K1,413,023
Paul Schimmel
Director
Oct 8, 2025Buy+682,001$0.90$613.80K1,095,024
Jane A. Gross
Director
Mar 17, 2025Buy+3,750$4.00$15.00K9,750
Nancy Denyes
General Counsel
Feb 4, 2025Sale−899$3.78$3.40K26,555
Jill Marie Broadfoot
Chief Financial Officer
Feb 4, 2025Sale−1,254$3.78$4.74K31,763
Nancy Denyes
General Counsel
Feb 3, 2025Option exercise+2,687––27,454
Jill Marie Broadfoot
Chief Financial Officer
Feb 3, 2025Option exercise+3,750––33,017
Sanjay Shukla
President and CEO, Director
Feb 3, 2025Option exercise+10,375––146,923
Paul Schimmel
Director
Jul 24, 2024Buy+52,300$1.93$100.94K413,023
Paul Schimmel
Director
Jul 23, 2024Buy+6,648$1.82$12.10K360,723
Paul Schimmel
Director
Jul 22, 2024Buy+41,052$1.74$71.43K354,075
Nancy Denyes
General Counsel
Jun 5, 2024Buy+5,000$1.86$9.30K22,267
Sanjay Shukla
President and CEO, Director
May 31, 2024Buy+20,000$1.81$36.20K136,548
Jill Marie Broadfoot
Chief Financial Officer
May 31, 2024Buy+5,000$1.79$8.95K27,960
Timothy Coughlin
Director
May 30, 2024Buy+50,000$1.75$87.50K56,000
Jill Marie Broadfoot
Chief Financial Officer
Feb 6, 2024Sale−1,590$1.69$2.69K20,821
Nancy Denyes
General Counsel
Feb 5, 2024Option exercise+2,688––14,767
Jill Marie Broadfoot
Chief Financial Officer
Feb 5, 2024Option exercise+3,750––22,411
Sanjay Shukla
President and CEO, Director
Feb 5, 2024Option exercise+10,375––116,548
Sanjay Shukla
President and CEO, Director
Dec 12, 2023Buy+12,000$1.18$14.16K106,173
Sanjay Shukla
President and CEO, Director
Dec 11, 2023Buy+3,000$1.17$3.51K94,173
Sanjay Shukla
President and CEO, Director
Nov 13, 2023Buy+13,578$1.11$15.07K91,173
Sanjay Shukla
President and CEO, Director
Nov 10, 2023Buy+1,422$1.14$1.62K77,595
Sanjay Shukla
President and CEO, Director
Jul 28, 2023Buy+15,000$2.01$30.15K76,173
Timothy Coughlin
Director
May 17, 2023Gift−6,000––0
Timothy Coughlin
Director
May 17, 2023Gift+6,000––6,000
Paul Schimmel
Director
May 10, 2023Buy+200,000$2.25$450.00K313,023
Svetlana Lucas
Director
Apr 26, 2023Option exercise+6,000––6,000
John K. Clarke
Director
Apr 26, 2023Option exercise+6,000––19,797
Jane A. Gross
Director
Apr 26, 2023Option exercise+6,000––6,000
Paul Schimmel
Director
Apr 26, 2023Option exercise+6,000––8,890
Sara Zaknoen
Director
Apr 26, 2023Option exercise+6,000––6,000
Timothy Coughlin
Director
Apr 26, 2023Option exercise+6,000––6,000
Jill Marie Broadfoot
Chief Financial Officer
Feb 6, 2023Sale−1,566$2.36$3.70K15,460
Sanjay Shukla
President and CEO, Director
Feb 3, 2023Option exercise+10,375––61,173
Jill Marie Broadfoot
Chief Financial Officer
Feb 3, 2023Option exercise+3,750––17,026
Nancy Denyes
General Counsel
Feb 3, 2023Option exercise+2,688––7,079
Sanjay Shukla
President and CEO, Director
Nov 21, 2022Buy+10,000$2.14$21.40K50,798
Sanjay Shukla
President and CEO, Director
Jul 1, 2022Buy+15,000$2.88$43.20K40,798
Jill Marie Broadfoot
Chief Financial Officer
Jan 13, 2022Buy+1,923$6.75$12.98K12,112
Sanjay Shukla
President and CEO, Director
Jan 7, 2022Buy+5,000$6.76$33.80K25,798
Sanjay Shukla
President and CEO, Director
Nov 15, 2021Buy+2,500$8.58$21.45K20,798
Paul Schimmel
Director
Sep 20, 2021Gift+250,000––679,143
Paul Schimmel
Director
Sep 20, 2021Buy+250,000$8.00$2.00M252,890
Paul Schimmel
Director
Sep 20, 2021Gift−250,000––2,890
John K. Clarke
Director
May 21, 2021Sale−2,500$4.34$10.85K108,083
Sanjay Shukla
President and CEO, Director
May 18, 2021Buy+10,000$4.01$40.10K18,298
Paul Schimmel
Director
May 18, 2021Buy+50,000$3.98$199.00K113,023
Sanjay Shukla
President and CEO, Director
Feb 9, 2021Sale−778$7.66$5.96K8,298
Jill Marie Broadfoot
Chief Financial Officer
Feb 9, 2021Sale−390$7.66$2.99K9,833
Sanjay Shukla
President and CEO, Director
Feb 6, 2021Option exercise+1,785––9,076
Jill Marie Broadfoot
Chief Financial Officer
Feb 6, 2021Option exercise+892––10,223
John K. Clarke
Director
Sep 2, 2020Sale−7,260$4.01$29.11K110,583

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
0.31%
0M shares short
Days to cover
3.4
At 0M shares a day
Change since last report
-97.1%
From 10M shares
Short volume, 20 days
58.2%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of aTYR PHARMA's stock actually held short. Settlement fails (shares not delivered on time) peaked at 13,043 shares on Sep 18, 2026 over the last 90 days.

See a number that looks wrong?